EXAMINE THIS REPORT ON HEMGENIX

Number of suitable people: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as acquiring gentle or moderate disease can have a extreme bleeding phenotyp